Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT04345627
Recruiting Observational

Japanese Lead Extraction Registry

NCT04345627 · tracked via the Priya Life Science Japan tracker
Sponsor
National Cerebral and Cardiovascular Center, Japan
Phase
Observational
Started
2018-07-01
Last updated
2023-11-13

Condition(s) studied

Arrhythmia, Cardiac

Study summary

Japanese Lead Extraction (J-LEX) Registry is an observational nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The acute success rate at discharge and the complications associated with transvenous lead extraction will be collected. J-LEX registry will provide a reliable information on indications, methods, the success rate, complications and the prognosis at 30 days prognosis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing transvenous lead extraction in Japan. Exclusion Criteria: * Patients who receive open-chest surgical extraction alone. * Patients who refused to consent.

Primary outcome measure(s)

  • Proportion of procedural success — Through discharge from hospital, approximately up to 2 weeks.
    Procedural success was defined as complete or partial and is identified for each lead extracted.

Trial sites (1)

FacilityCityRegionStatus
National Cerebral and Cardiovascular Center Suita Osaka Recruiting

More National Cerebral and Cardiovascular Center, Japan trials in Japan

Japanese Catheter Ablation Registry Recruiting
REASSURE-NIRS Registry Recruiting
National Cerebral and Cardiovascular Center (NCVC) Stroke Registry Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04345627 on ClinicalTrials.gov ↗ ← All trials in Japan